NYX-2925 Continues to Significantly Reduce Pain Severity Marker in Phase 2 Trial, Top Line Data Shows

NYX-2925 Continues to Significantly Reduce Pain Severity Marker in Phase 2 Trial, Top Line Data Shows
Aptinyx's NYX-2925 treatment candidate continues to significantly reduce the levels of a brain biomarker associated with pain severity, called glutamine (Glx), in people with fibromyalgia, top line results of a Phase 2 pilot trial show. The findings also showed improvements in patient-reported pain, as well as a reduction in fibromyalgia’s impact on daily living. “The statistically significant effects on both pain-related brain activity and patient-reported clinical measures elegantly demonstrates that NYX-2925 is acting in the brain to alter pain processing, leading to pain alleviation,” Norbert Riedel, president and CEO of Aptinyx, said in a press release. “The results with NYX-2925 are compelling and compare very favorably with the effects of approved fibromyalgia drug treatments we previously evaluated in separate and similar studies,” added Daniel Clauw, an investigator in this trial and a professor at the University of Michigan. NYX-2925 is an oral therapy that acts to modulate the NMDA receptor, which is key in neuronal communication, and is involved in regulating pain signals in the brain and spinal cord. NYX-2925 alters neural cell communication, and is seen as a potential therapy to lessen pain and other symptoms associated with chronic pain. In preclinical models of different neuropathic pain conditions, NYX-2925 showed robust efficacy, and a favorable safety profile. Then, in a Phase 1 clinical trial (NCT02834741) with healthy individuals, NYX-2925 was well-tolerated across a wide range of doses. Now, researchers report top-line results from the ongoing Phase 2 trial (NCT03249103), which is testing the efficacy and safety of daily oral treatment with 20 mg and 200 mg of NYX-2925, as well as a placebo, over six weeks in people with
Subscribe or to access all post and page content.